Please assess the completion status of the following clinical trial:

Trial Title: SPK Study in Afghanistan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males: age over 4 months;~* Females: age 4 months - 11 years inclusive, or 18 years or older;~* Infection with P. falciparum detected by microscopy at a level of 500-150,000/µL asexual forms;~* Presence of axillary or tympanic temperature ≥ 37.5 °C or oral or rectal temperature of ≥ 38 °C or history of fever during the past 24 h;~* ability to swallow oral medication;~* ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the patient or from a parent or guardian in the case of children under 16 years of age.~Exclusion Criteria:~* Presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);~* Infection with another Plasmodium species detected by microscopy not mixed with falciparum;~* Females 18 years or older: a positive pregnancy test or absence of a negative pregnancy test when a pregnancy test is not possible for cultural reasons;~* Breastfeeding~* Presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm);~* Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);~* Regular medication, which may interfere with antimalarial pharmacokinetics;~* History of hypersensitivity reactions or contraindications to any of the study medications;

- Gender: ALL
- Minimum Age: 4 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artesunate + Sulphadoxine-pyrimethamine (Type: EXPERIMENTAL): AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date.

Based on this trial design, predict the completion outcome and termination type (if applicable).